๐๐ข๐ฉ๐จ๐ฉ๐ซ๐จ๐ญ๐๐ข๐ง(๐) โ
๐๐ง๐๐-๐ข๐ง-๐-๐๐ข๐๐๐ญ๐ข๐ฆ๐ ๐๐๐ฌ๐ญ ๐จ๐ซ ๐๐จ๐๐ฌ ๐๐ญ ๐๐๐๐ ๐๐๐ฉ๐๐๐ญ๐ข๐ง๐ ?
Lipoprotein(a) is predominantly genetically determined and remains relatively stable throughout adult life. Therefore, unlike LDL-C, it generally does not require regular serial monitoring.
๐๐ก๐จ ๐๐ก๐จ๐ฎ๐ฅ๐ ๐๐ ๐๐๐ฌ๐ญ๐๐?
โ Measure Lp(a) at least once in every adultโs lifetime as part of cardiovascular risk assessment.
โ Testing is particularly important in patients with:
โPremature ASCVD or a strong family history of premature ASCVD
โFamilial hypercholesterolaemia
โRecurrent cardiovascular events despite apparently optimal LDL-C control
โA family history of markedly elevated Lp(a)
โ If Lp(a) is markedly elevated, consider testing first-degree relatives.
๐๐ก๐๐ญ ๐๐ฌ ๐๐จ๐ง๐ฌ๐ข๐๐๐ซ๐๐ ๐๐ฅ๐๐ฏ๐๐ญ๐๐?
Lp(a) โฅ50 mg/dL or โฅ125 nmol/L is generally considered an important ASCVD risk-enhancing level.
Important: mg/dL and nmol/L should not be directly converted using a single fixed conversion factor, because apo(a) particle size varies between individuals.
If Lp(a) Is Elevated โ How Often Should It Be Repeated?
โ Routine annual or 6-monthly measurement is generally NOT required.
โ If the patient is clinically stable and the initial measurement is reliable, an elevated Lp(a) can generally be regarded as a persistent lifelong cardiovascular risk factor.
๐๐ก๐๐ง ๐๐ก๐จ๐ฎ๐ฅ๐ ๐๐ฉ(๐) ๐๐ ๐๐๐ฉ๐๐๐ญ๐๐?
Repeat measurement may be reasonable when:
โThe initial result is borderline or uncertain and confirmation would affect risk assessment.
โThe initial measurement was obtained during a significant acute inflammatory or medical illness.
โThere has been a major change in a condition that can influence Lp(a), such as kidney, liver or thyroid disease.
โThere are major hormonal changes, such as pregnancy or menopause, where reassessment is clinically relevant.
โA patient starts a specific Lp(a)-lowering treatment, particularly as dedicated Lp(a)-targeted therapies become available.
๐๐ก๐๐ญ ๐๐ก๐จ๐ฎ๐ฅ๐ ๐๐ ๐๐จ ๐๐ก๐๐ง ๐๐ฉ(๐) ๐๐ฌ ๐๐ข๐ ๐ก?
At present, the main clinical response is not repeated measurement of Lp(a) but more intensive management of the patientโs overall cardiovascular risk.
๐
๐จ๐๐ฎ๐ฌ ๐ฉ๐๐ซ๐ญ๐ข๐๐ฎ๐ฅ๐๐ซ๐ฅ๐ฒ ๐จ๐ง:
โ Aggressive LDL-C reduction according to the patientโs overall ASCVD risk
โ Optimal blood-pressure control
โ Diabetes management
โ Smoking cessation
โ Healthy weight, diet and regular physical activity
โ Assessment and treatment of other modifiable cardiovascular risk factors
1September 6, 2026 273 1
